.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Lung adenocarcinoma (LUAD) remains a leading cause of cancer-related mortality globally, necessitating the identification of novel molecular markers for early diagnosis and targeted therapy. Recent genomic and transcriptomic studies have highlighted the role of mitochondrial subunits in tumor biology. Specifically, research into NDUFA10 in lung adenocarcinoma has revealed its potential as a critical oncogenic driver that facilitates tumor progression and metastasis. This subunit of NADH:ubiquinone oxidoreductase (Complex I) appears to be a key downstream effector in signaling pathways that promote malignancy.
Expression analyses using large-scale databases like TCGA and TIMER have confirmed that NDUFA10 mRNA and protein levels are significantly upregulated in LUAD tissues compared to adjacent normal tissues. This elevation is not merely a bystander effect; rather, it correlates strongly with advanced clinical parameters. Patients with high NDUFA10 expression often present with advanced N stages (N2/N3) and higher pathological stages (III/IV). Furthermore, elevated levels are associated with a significant decrease in overall survival (OS) and first progression (FP) intervals, marking NDUFA10 as a robust biomarker for poor prognosis.
The role of NDUFA10 in lung adenocarcinoma extends to the regulation of cellular plasticity and movement. Gene Set Enrichment Analysis (GSEA) suggests that this gene is intricately involved in the WNT and Notch signaling pathways. Additionally, it appears to modulate the TGFβ pathway, which is a well-known regulator of the epithelial-mesenchymal transition (EMT). By facilitating EMT, NDUFA10 promotes the migration and invasion of cancer cells. In vitro experiments have demonstrated that silencing NDUFA10 via knockdown significantly inhibits cell proliferation, colony formation, and invasive capabilities, suggesting its potential as a therapeutic target.
Beyond its role in cell growth, NDUFA10 expression is linked to the tumor immune microenvironment. Studies indicate a correlation between high NDUFA10 levels and poor efficacy of anti-PD-1/PD-L1 antibody therapies. This suggests that mitochondrial metabolism may influence immune evasion in LUAD. Future research aims to further elucidate the crosstalk between NDUFA10, reactive oxygen species (ROS) production, and energy metabolism to develop more effective combinatorial treatment strategies for patients with advanced lung cancer.
High expression of NDUFA10 is a negative prognostic indicator. It is associated with shorter overall survival, advanced pathological stages, and a higher likelihood of lymph node metastasis in patients with lung adenocarcinoma.
While still in the experimental phase, in vitro studies show that silencing NDUFA10 suppresses the proliferation and migration of LUAD cells. This suggests that targeting NDUFA10 or its associated pathways (like WNT/Notch) could be a viable strategy for future therapies.
Elevated NDUFA10 levels have been associated with the best efficacy outcomes in some cohorts but also suggest resistance in others; primarily, it serves as a marker for altered immune infiltration and poorer response to standard anti-PD-1/PD-L1 treatments in advanced cases.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
New research identifies NDUFA10 as a key driver of metastasis in lung adenocarcinoma, correlating with poor prognosis and anti-PD-1/PD-L1 therapy resistance...
5 months ago
A clinical comparison of extravascular and subcutaneous implantable cardioverter-defibrillators, detailing patient selection, pacing capabilities, and implantation nuances.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
A meta-analysis of 13 propensity score-matched studies shows ViV-TAVR delivers lower early mortality and reduced bleeding compared to redo-SAVR for degenerated bioprosthetic aortic valves, though long-term hemodynamics warrant careful anatomical and patient-centered evaluation.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
